SEC FORM
3
SEC Form 3
FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL |
OMB Number: |
3235-0104 |
Estimated average burden |
hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person*
499 PARK AVENUE, 25TH FLOOR |
|
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 12/07/2012
|
3. Issuer Name and Ticker or Trading Symbol
ACELRX PHARMACEUTICALS INC
[ ACRX ]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
Director |
X |
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Form filed by One Reporting Person |
X |
Form filed by More than One Reporting Person |
|
Table I - Non-Derivative Securities Beneficially Owned |
1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Common Stock |
5,008,400 |
I |
See Footnotes
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
1. Name and Address of Reporting Person*
499 PARK AVENUE, 25TH FLOOR |
|
(Street)
|
1. Name and Address of Reporting Person*
C/O PERCEPTIVE ADVISORS LLC |
499 PARK AVENUE, 25TH FLOOR |
(Street)
|
1. Name and Address of Reporting Person*
C/O PERCEPTIVE ADVISORS LLC |
499 PARK AVENUE, 25TH FLOOR |
(Street)
|
Explanation of Responses: |
|
/s/ Joseph Edelman, managing member of Perceptive Advisors LLC |
12/13/2012 |
|
** Signature of Reporting Person |
Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* If the form is filed by more than one reporting person,
see
Instruction
5
(b)(v). |
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
Exhibit 24
Information Regarding Joint Filers
Designated Filer of Form 3: Perceptive Advisors LLC
Date of Earliest Transaction Required to be Reported: December 7, 2012
Issuer Name and Ticker Symbol: AcelRx Pharmaceuticals, Inc. [ACRX]
Names: Perceptive Life Sciences Master Fund Ltd. and Joseph Edelman
Address: Perceptive Advisors LLC
499 Park Avenue, 25th Floor
New York, NY 10022
Signatures:
The undersigned, Perceptive Life Sciences Master Fund Ltd. and Joseph Edelman
are jointly filing the attached Statement of Beneficial Ownership of
Securities on Form 3 with Perceptive Advisors LLC with respect to the
beneficial ownership of securities of AcelRx Pharmaceuticals, Inc
Perceptive Life Sciences Master Fund Ltd.
By: Perceptive Advisors LLC, its investment manager
By: /s/ Joseph Edelman
-------------------------------------------------
Joseph Edelman, managing member
JOSEPH EDELMAN
/s Joseph Edelman
--------------------------------------------------
By: Joseph Edelman